ERBB2 and breast neoplasm: They found that the cytotoxic effect of dimeric ZHER2 affibody on the SK-BR-3 cell line is comparable to trastuzumab (Herceptin®) as an FDA-approved therapeutic monoclonal antibody routinely used for the treatment of patients with HER2-positive breast tumors (43).